Badawi R, Fahmy Abou Taira N, Hasby S, Elkhalawany W, Elrefaey W, Ahmed Khalf N
Saudi Med J. 2024; 45(10):1034-1040.
PMID: 39379109
PMC: 11463562.
DOI: 10.15537/smj.2024.45.10.20240393.
Gurun M, Brennan P, Handjiev S, Khatib A, Leith D, Dillon J
PLoS One. 2024; 19(4):e0299507.
PMID: 38625981
PMC: 11020899.
DOI: 10.1371/journal.pone.0299507.
Butcko A, Putman A, Mottillo E
Antioxidants (Basel). 2024; 13(1).
PMID: 38247511
PMC: 10812494.
DOI: 10.3390/antiox13010087.
Karjoo S, Auriemma A, Fraker T, Bays H
Obes Pillars. 2023; 3:100027.
PMID: 37990727
PMC: 10661876.
DOI: 10.1016/j.obpill.2022.100027.
Zhao J, Xu X, Wei X, Zhang S, Xu H, Wei X
Biomedicines. 2023; 11(9).
PMID: 37760857
PMC: 10525902.
DOI: 10.3390/biomedicines11092416.
Five-Aminolevulinic Acid (5-ALA) Induces Heme Oxygenase-1 and Ameliorates Palmitic Acid-Induced Endoplasmic Reticulum Stress in Renal Tubules.
Hamada S, Mae Y, Takata T, Hanada H, Kubo M, Taniguchi S
Int J Mol Sci. 2023; 24(12).
PMID: 37373300
PMC: 10299457.
DOI: 10.3390/ijms241210151.
The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.
Hydes T, Kennedy O, Buchanan R, Cuthbertson D, Parkes J, Fraser S
BMC Med. 2023; 21(1):185.
PMID: 37198624
PMC: 10193672.
DOI: 10.1186/s12916-023-02891-x.
Non-alcoholic fatty liver disease in diabetes mellitus patients on chronic hemodialysis - A case series addressing cardiovascular and mortality risks.
Stoica R, Tribus L, Marin R, David T, Preda C, Bica I
Front Clin Diabetes Healthc. 2023; 4:1113666.
PMID: 36993819
PMC: 10012059.
DOI: 10.3389/fcdhc.2023.1113666.
Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan.
Ersoy Yesil E, Yilmaz Y, Yesil A, Mese M, Kaya E, Bakir E
Hepatol Forum. 2023; 4(1):14-18.
PMID: 36843889
PMC: 9951894.
DOI: 10.14744/hf.2022.2022.0038.
Poor Outcomes of Patients With NAFLD and Moderate Renal Dysfunction or Short-Term Dialysis Receiving a Liver Transplant Alone.
Fernandez-Carrillo C, Li Y, Ventura-Cots M, Argemi J, Dai D, Clemente-Sanchez A
Transpl Int. 2022; 35:10443.
PMID: 36568138
PMC: 9784907.
DOI: 10.3389/ti.2022.10443.
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease.
Han E
Diabetes Metab J. 2022; 46(4):564-566.
PMID: 35929174
PMC: 9353564.
DOI: 10.4093/dmj.2022.0203.
MAFLD and CKD: An Updated Narrative Review.
Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A
Int J Mol Sci. 2022; 23(13).
PMID: 35806010
PMC: 9266672.
DOI: 10.3390/ijms23137007.
Development and implementation of patient-level prediction models of end-stage renal disease for type 2 diabetes patients using fast healthcare interoperability resources.
Wang S, Han J, Jung S, Oh T, Yao S, Lim S
Sci Rep. 2022; 12(1):11232.
PMID: 35789173
PMC: 9253099.
DOI: 10.1038/s41598-022-15036-6.
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.
Kaya E, Yilmaz Y
J Clin Transl Hepatol. 2022; 10(2):329-338.
PMID: 35528971
PMC: 9039705.
DOI: 10.14218/JCTH.2021.00178.
Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Zhao P, Yan J, Pan B, Liu J, Fu S, Cheng J
Diabetes Metab Syndr Obes. 2022; 15:1141-1151.
PMID: 35444436
PMC: 9015107.
DOI: 10.2147/DMSO.S356497.
Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model.
Hamada S, Takata T, Yamada K, Yamamoto M, Mae Y, Iyama T
PLoS One. 2022; 17(3):e0265461.
PMID: 35294499
PMC: 8926260.
DOI: 10.1371/journal.pone.0265461.
Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease.
Tao Z, Li Y, Cheng B, Zhou T, Gao Y
J Clin Transl Hepatol. 2022; 10(1):164-173.
PMID: 35233386
PMC: 8845149.
DOI: 10.14218/JCTH.2021.00171.
Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes.
Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F
J Clin Med. 2022; 11(4).
PMID: 35207239
PMC: 8878156.
DOI: 10.3390/jcm11040968.
The association between NAFLD and risk of chronic kidney disease: a cross-sectional study.
Cao Y, Deng Y, Wang J, Zhao H, Zhang J, Xie W
Ther Adv Chronic Dis. 2021; 12:20406223211048649.
PMID: 34777740
PMC: 8586173.
DOI: 10.1177/20406223211048649.
1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease.
Trindade A, Thaniyavarn T, Hashemi N, Coppolino 3rd A, Kennedy J, Mallidi H
ERJ Open Res. 2021; 7(3).
PMID: 34435032
PMC: 8381158.
DOI: 10.1183/23120541.00103-2021.